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Received August 1, 2011; accepted March 30, 2012AbstractA 67-year-old woman presented with a history of dilated cardiomyopathy with congestive heart failure since 2003, who subsequently
developed lower rectal cancer (adenocarcinoma) with liver, bone, and lymph node metastasis. Abdominoperineal resection and hepatectomy
were performed. The patient received two rounds of intravenous chemotherapy, including 12 and six courses of FOLFOX4 (5-fluorouracil,
leucovorin, and oxaliplatin; 85 mg/m2 per cycle). She underwent a third round of intravenous FOLFOX4 because of tumor progression. During
the 21st course of FOLFOX4 regimen, the patient developed ST segment depression in lead II and prolongation of QT interval with polymorphic
ventricular tachycardia, torsades de pointes right after the start of oxaliplatin infusion. Immediate defibrillation and cardiopulmonary resusci-
tation were administered, and the patient regained spontaneous circulation and consciousness. Twelve-lead electrocardiogram showed ST
segment elevation in III, aVF, and ST segment depression in V4e6 after resuscitation. To our knowledge, prolongation of QT interval with
torsades de pointes and coronary spasm with myocardial injury that were stabilized in one patient following oxaliplatin infusion has not been
reported. We present a patient with these rare complications.
Copyright  2013 Elsevier Taiwan LLC and the Chinese Medical Association. All rights reserved.
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Oxaliplatin (Eloxatin; Sanofi-Synthelabo, New York, NY,
USA) is the only third-generation platinum derivative routinely
used in cancer therapy. It is particularly useful in the treatment of
colorectal cancer. The acute toxicities of oxaliplatin include
nausea, vomiting, diarrhea, neutropenia, thrombocytopenia,
peripheral sensory neuropathy, and hypersensitivity reaction.1* Corresponding author. Dr. Rei-Yeuh Chang, Division of Cardiology,
Department of Internal Medicine, Ditmanson Medical Foundation Chia-Yi
Christian Hospital, 539, Jhongsiao Road, Chia-Yi 600, Taiwan, ROC.
E-mail address: changry77@gmail.com (R.-Y. Chang).
1726-4901/$ - see front matter Copyright  2013 Elsevier Taiwan LLC and the C
http://dx.doi.org/10.1016/j.jcma.2013.05.001Hypersensitivity reactions to oxaliplatin vary from mild symp-
toms to severe anaphylactic shock, and may be life-threatening.
The major manifestations of severe anaphylactic reaction
include bronchospasm, tachycardia, hypertension or hypoten-
sion, and even cardiopulmonary arrest. Severe anaphylactic
reaction and cardiac toxicity are rare, and the incidence in-
creases when patients receive accumulated doses of oxalipla-
tin.2One case of oxaliplatin-induced coronary artery spasmwith
acute myocardial injury has been reported and associated with
sensory neuropathy.3 Oxaliplatin-induced long QT syndrome
(LQTS) has been reported in a patient with appendiceal
adenocarcinoma.4 To our knowledge, prolongation of QT in-
terval with torsades de pointes (TdP) and coronary spasm withhinese Medical Association. All rights reserved.
Fig. 2. Electrocardiographic recording (lead II) by monitor showed ST
segment depression and prolonged QT/QTc interval of 480/628 milliseconds
after (A) oxaliplatin infusion and (B) TdP polymorphic ventricular
tachycardia.
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infusion has not been reported. We report this rare complication
in a patient with dilated cardiomyopathy and rectal cancer after
prolonged use of oxaliplatin therapy.
2. Case report
A 67-year-old woman had dilated cardiomyopathy with
congestive heart failure since February 2003, and subsequently
developed lower rectum cancerwith liver, bone, and lymph node
metastasis (adenocarcinoma, T3N2M1, stage IV) in February
2007. Abdominoperineal resection and hepatectomy were per-
formed, and she received 12 courses of the oxaliplatin regimen
known as FOLFOX4 (5-fluorouracil, leucovorin, and oxalipla-
tin; 85 mg/m2 per cycle). She underwent another six courses of
FOLFOX4 plus Erbitux in 2010. Because of bone metastasis in
the sacrum with severe bone pain, she received local radio-
therapy and a third round of intravenous FOLFOX4 infusion for
tumor progression in 2011. In April 2011, she was admitted for
another course of FOLFOX4 therapy (a total of 21 courses).
Upon admission, the 12-lead electrocardiogram (ECG) showed
atrial fibrillation with rapid ventricular response, nonspecific
ST-T change, and normal QT/QTc intervals (Fig. 1). However,
the patient experienced tightness of the throat soon after the start
of oxaliplatin infusion, as well as cold sweat and hypotension
thereafter. On the ECG, there was a downsloping ST segment
depression at lead II, prolonged QT/QTc interval of 480/628
milliseconds measured by an average of three sequential beats
(Fig. 2A). Suddenly, the patient lost consciousness and exhibited
no pulse. Her ECGmonitor showed ventricular tachycardia, like
TdP (Fig. 2B). Immediate defibrillation was carried out, using
direct current shocks of asynchronizedmonophasic energy 300 J
and cardiopulmonary resuscitation. Intravenous epinephrine
bolus and dopamine infusion were also administered. The pa-
tient regained spontaneous circulation and consciousness.
Twelve-lead ECG showed ST segment elevation in III, aVF, ST
segment depression inV4e6, and prolongedQT/QTc interval ofFig. 1. Twelve-lead electrocardiogram (ECG) showed atrial fibrillation with rapid v
and QTc interval of 370 milliseconds.320/459 milliseconds after resuscitation (Fig. 3). Electrolyte
and cardiac enzyme levels were within normal limits: sodium
135 mmol/L (range: 135e147 mmol/L), potassium 4.10 mmol/
L (range: 3.5e4.9 mmol/L), calcium 8.9 mg/dL (range:
8.5e10.5 mg/dL), magnesium 2.46 mg/dL (range: 1.6e2.6 mg/
dL), CPK 54 IU/L (range: 38e174 IU/L), CK-MB 1.70 U/L
(range: 3e10 U/L), and troponin-I 0.047 ng/mL (normal limit
<0.5 ng/mL). Follow-up ECG showed a normal QT/QTc in-
terval of 348/397 milliseconds on the 4th day after the patient’s
cardiac event. Cardiac catheterization showed normal coronary
angiography, mild global hypokinesis of the left ventricle, and
mild mitral regurgitation. The patient recovered from the side
effects of oxaliplatin and was eventually discharged.entricular response, nonspecific ST-T change, QT interval of 300 milliseconds,
Fig. 3. Electrocardiography showed ST segment elevation over lead II, III, aVF, and ST segment depression, prolonged QT/QTc interval of 320/459 milliseconds
over V4-6 after cardiopulmonary resuscitation.
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Allergic reactions to oxaliplatin vary, which canmanifestmild
to severe symptoms, and even life-threatening anaphylactic
shock.Maindrault-Goebel et al5 retrospectively analyzed the type
and frequency of allergic reactions to oxaliplatin in 42 cancer
patients. They reported type I immediate allergic reactions (res-
piratory in 47.6%, cutaneous in 40.5%, and anaphylactic shock in
3.1% of cases) and type II allergy (immunological thrombocy-
topenia in 3.1% of cases).5 We previously reported severe
anaphylactic reactions in 1.32% of patients receiving oxaliplatin
therapy.6 Anaphylaxis is immunoglobulin E mediated, and often
rapid in its onset. Symptoms follow the release of potent chemical
mediators from previously sensitized mast cells on antigen pre-
sentation.7 The bridging of immunoglobulin E molecules
attached to the mast cell surface activates an established pathway
ending in mast cell granule release of histamine, heparin, and
proteases, aswell as the synthesis and secretion of leukotriene and
prostaglandin mediators of anaphylaxis.8 The direct vasoactive
and smooth muscle spasmogenic effect of these mediators can
cause coronary spasm. Coronary spasm in response to vasocon-
strictor stimuli was observed in arterial segments with or without
organic stenosis.9 Most spasms were superimposed on fixed
atherosclerotic lesions in 60% of the patients.10 However, the
occurrence of coronary spasm andmyocardial injury precipitated
by anaphylaxis in a patient with dilated cardiomyopathy and
normal coronary angiography is rare.
In the present case, chest tightness and hypotension
developed immediately after the 21st cycle of oxaliplatin
infusion and was associated with ST segment downsloping
depression in lead II and prolongation of QT interval. More-
over, this was followed by life-threatening arrhythmia. The
proposed mechanism of hypotension and TdP is anaphylactic
coronary spasm combined with oxaliplatin-induced QT pro-
longation, which is possibly due to the sodium channelopathy
after cumulative doses.
Oxaliplatin is associated with several toxicities, the most
common of which include nausea, vomiting, fatigue, diarrhea,neutropenia, and thrombocytopenia. Oxaliplatin accumulation
is associated with its most characteristic and dose-limiting
toxicitydsensory neuropathy. Oxaliplatin may also induce
acute and chronic peripheral neuropathies. Acute peripheral
neuropathy may be linked to the rapid chelation of calcium by
the oxaliplatin metabolite oxalate and oxaliplatin-induced
change in voltage-gated sodium channels through a pathway
involving calcium ions.11 A sodium channel is needed for
impulse conduction by cardiac myocytes and cells of the
HisePurkinje system.12 The change in sodium channel ki-
netics may predispose oxaliplatin-treated patients to LQTS
and TdP. The incidence of acute oxaliplatin-induced peripheral
neuropathy is quite high, ranging from 65% to 98%.13 How-
ever, cardiac toxicity of oxaliplatin has rarely been reported.
QT prolongation following the 11th cycle of oxaliplatin infu-
sion was reported in one patient who did not develop TdP. The
predictors of TdP in drug-induced LQTS include a >0.28-
second interval between the peak and end of the T-wave, T-
wave alternans, increased beat-to-beat QT variability, and
early afterdepolarizations.14 Other risk factors for drug-
induced LQTS include the female gender and hypokale-
mia.15 Whether the accumulated dosage of oxaliplatin is
related to cardiac toxicity warrants further study.
In conclusion, oxaliplatin is currently a cornerstone in the
treatment of the early and late stage of colorectal cancer.
Prolonged and repeated use of oxaliplatin in late-stage patients
may induce sensory neuropathy. Cardiac toxicity manifested
by anaphylaxis and prolongation of QT interval with TdP is
potentially life-threatening. Consequently, clinicians should
keep in mind risk factors that could lead to prolongation of QT
interval and TdP in patients with cumulative doses of oxali-
platin therapy.References
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